HRTISHerantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead p…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
Herantis Pharma PLC (OHEL:HRTIS) (H1 2026) Earnings Call Highlights: Promising Phase 2 ... Positive Phase 1 data for HER96 demonstrated favorable safety, tolerability, efficient brain penetration, and strong biomarker signals consistent with the proposed mechanism of action. The company has a broad mechanism of action targeting the core biology of Parkinson's disease, offering potential for neurorestoration, which differentiates it from competitors with more narrow approaches. Secured a non-dilutive 8 million Horizon Europe grant to support the Phase 2 trial, supplementing the company's financing and reducing the need for dilutive capital. | ||